Patents by Inventor Richard Alexander BOUGLAS

Richard Alexander BOUGLAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS
    Publication number: 20170121322
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory 3,4-dihydropyrido[2,3-b]pyrazinones with a meta-substituted aromatic amino or ether group of the general formula (I) in which A, X, Y, R1, R2, R3, R4, R5, R6 and n are each as defined in the description, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of tumour disorders. Furthermore, this invention relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: June 15, 2015
    Publication date: May 4, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Norbert SCHMEES, Bernard HAENDLER, Detlef STÖCKIGT, Richard Alexander BISSELL, Richard Alexander BOUGLAS, Ian STEFANUTI, Stephan SIEGEL
  • MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES
    Publication number: 20160176867
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory, dihydroquinoxalinones and dihydropyridopyrazinones of the general formula (I) in which A, X, R1, R2, R3, R4, R5, R6 and n are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. This invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammation diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: July 7, 2014
    Publication date: June 23, 2016
    Inventors: Norbert SCHMEES, Bernard HAENDLER, Detlef STÖCKIGT, Daniel GALLENKAMP, Richard BISSELL, Richard Alexander BOUGLAS